Table 6.
Predictive value of TyG index for primary endpoint and each component in univariate and multivariate analysis
| Univariate analysis | Multivariate analysisc | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| TyG index as a nominal variablea | ||||||
| Primary endpoint | 4.610 | 3.253–6.533 | < 0.001 | 4.062 | 2.732–6.040 | < 0.001 |
| All-cause death | 2.103 | 0.705–6.276 | 0.183 | 0.872 | 0.179–4.258 | 0.866 |
| Non-fatal MI | 3.744 | 1.767–7.935 | 0.001 | 2.260 | 0.894–5.715 | 0.085 |
| Ischemia-driven revascularization | 4.920 | 3.218–7.521 | < 0.001 | 4.980 | 3.075–8.067 | < 0.001 |
| TyG index as a continuous variableb | ||||||
| Primary endpoint | 3.367 | 2.677–4.235 | < 0.001 | 3.208 | 2.400–4.289 | < 0.001 |
| All-cause death | 1.358 | 0.610–3.024 | 0.454 | 0.429 | 0.111–1.659 | 0.220 |
| Non-fatal MI | 4.449 | 2.684–7.373 | < 0.001 | 3.332 | 1.730–6.415 | < 0.001 |
| Ischemia-driven revascularization | 2.874 | 2.216–3.727 | < 0.001 | 3.021 | 2.167–4.211 | < 0.001 |
Italic values indicate statistically significant associations
TyG triglyceride glucose, MI myocardial infarction, HR hazard ratio, CI confidence interval
aThe HR was examined regarding lower TyG index as reference (stratified by the optimal cutoff point of TyG index determined by ROC curve analysis)
bThe HR was examined by per 1-unit increase of TyG index
cThe multivariate analysis was performed by using Model 4 [adjusted for age, sex (female), BMI, SBP, DBP, smoking, drinking, duration of diabetes, dyslipidemia, prior MI, PCI, stroke, PVD, diagnosis (NSTEMI), TC, HDL-C, eGFR, HbA1c, LVEF, SYNTAX score, LM treatment, DCB use, complete revascularization, number of stents, DAPT at discharge, DAPT interruption in 12 months, statins at discharge, statins interruption in 12 months, oral hypoglycemic agents (metformin, alpha-glucosidase inhibitor, sulfonylurea, dipeptidyl peptidase 4 inhibitor) at discharge and insulin at discharge]